AVN 322

Drug Profile

AVN 322

Alternative Names: AVN-322

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator ChemDiv
  • Developer AllaChem; Avineuro Pharmaceuticals
  • Class Nootropics; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 12 Sep 2016 Phase-II clinical trials in Alzheimer's disease in USA before September 2016 (Spring Bank Pharmaceuticals pipeline, September 2016)
  • 13 Nov 2013 Phase-I development is ongoing in USA
  • 13 Nov 2013 AVN 322 sublicensed to AllaChem before Nov 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top